SHR-1209
Hypercholesterolemia
Key Facts
About Jiangsu Hengrui Medicine
Jiangsu Hengrui Medicine's mission is to advance healthcare through high-quality, innovative medicines, solidifying its position as China's largest and most valuable pharmaceutical company. Its key achievements include building a massive pipeline of 719 drug candidates, successfully launching multiple blockbuster oncology drugs in China, and establishing international R&D footprints. The company's strategy centers on aggressive investment in proprietary R&D, a dual-track approach of 'innovation + internationalization,' and dominating key therapeutic areas like oncology while expanding into metabolic, autoimmune, and neurological diseases.
View full company profileTherapeutic Areas
Other Hypercholesterolemia Drugs
| Drug | Company | Phase |
|---|---|---|
| VXX-401 | Vaxxinity | Phase 1 |
| Atorvastatin Oral Liquid Suspension | CMP Pharma | Approved |
| AFFITOPE® AT04 (licensed to Frontier Biotech) | AFFiRiS | Phase 1 |
| AQR-008 | Aqur Biosciences | Pre-clinical |
| Leqvio® (inclisiran) | Novartis | Approved |
| MK-0616 | Merck | Phase 3 |
| IBI-306 | Innovent Biologics | NDA Submitted |
| Inusiran (AK102) | Akeso | Approved |
| Obicetrapib + Ezetimibe FDC | NewAmsterdam Pharma Company | Phase 3 |